Elicera Therapeutics AB (OSTO:ELIC) Total Assets : kr41.41 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Total Assets?

Elicera Therapeutics AB's Total Assets for the quarter that ended in Mar. 2024 was kr41.41 Mil.

During the past 12 months, Elicera Therapeutics AB's average Total Assets Growth Rate was -65.60% per year. During the past 3 years, the average Total Assets Growth Rate was -8.00% per year.

During the past 5 years, Elicera Therapeutics AB's highest 3-Year average Total Assets Growth Rate was 62.10%. The lowest was -8.00%. And the median was 27.05%.

Total Assets is connected with ROA %. Elicera Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2024 was -60.01%. Total Assets is also linked to Revenue through Asset Turnover. Elicera Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Elicera Therapeutics AB Total Assets Historical Data

The historical data trend for Elicera Therapeutics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Total Assets Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

0.62

12.59

54.74

46.31

30.18

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial													43.84	41.03	28.15	30.18	41.41

Elicera Therapeutics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Elicera Therapeutics AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	11.401	+	18.779
	=	30.18

Elicera Therapeutics AB's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	31.619	+	9.794
	=	41.41

Elicera Therapeutics AB (OSTO:ELIC) Total Assets Explanation

Total Assets is connected with ROA %.

Elicera Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-21.48	/	( (30.18	+	41.412)	/ 2 )
	=	-21.48	/	35.796
	=	-60.01 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Elicera Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (30.18	+	41.412)	/ 2 )
=	0	/	35.796
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Elicera Therapeutics AB Total Assets Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines